ABSTRACT
INTRODUCTION: The "Programme d'Accompagnement du retour à Domicile" (PRADO) COPD is a home discharge support program dedicated to organizing care pathways following hospitalization for COPD exacerbation. This study aimed at assessing its medico-economic impact. METHODS: This was a retrospective database study of patients included in the PRADO BPCO between 2017 and 2019. Data were extracted from the National Health Data System. A control group was built using propensity score matching. Morbi-mortality and costs (national health insurance perspective) were measured during the year following hospitalization. RESULTS: While the proportion of patients with a care pathway complying with recommendations from the National Health Authority was higher in the PRADO group, there was no significant effect on mortality and 12-month rehospitalization. In the PRADO group, the rehospitalization rate was lower when the care pathway was optimal. Healthcare costs per patient were 670 higher in the PRADO group. CONCLUSIONS: The PRADO COPD improves quality of care but without decreasing rehospitalizations and mortality, although rehospitalizations did decrease among PRADO group patients benefiting from an optimal care pathway.
Subject(s)
Health Care Costs , Patient Readmission , Pulmonary Disease, Chronic Obstructive , Humans , Male , Female , Pulmonary Disease, Chronic Obstructive/therapy , Pulmonary Disease, Chronic Obstructive/economics , Retrospective Studies , Aged , Middle Aged , Health Care Costs/statistics & numerical data , Health Care Costs/standards , Aged, 80 and over , Patient Readmission/statistics & numerical data , Patient Readmission/economics , Patient Discharge/statistics & numerical data , Patient Discharge/standards , Patient Discharge/economics , Home Care Services/economics , Home Care Services/standards , Home Care Services/statistics & numerical data , Home Care Services/organization & administration , Hospitalization/economics , Hospitalization/statistics & numerical data , France/epidemiology , Program Evaluation , Cost-Benefit AnalysisSubject(s)
Neurodermatitis , Prurigo , Chronic Disease , France/epidemiology , Humans , Prevalence , Prurigo/epidemiology , Prurigo/therapyABSTRACT
OBJECTIVE: To estimate the costs of healthcare resource consumption in the year preceding and the year following a myocardial infarction (MI). PATIENTS AND METHODS: A historical cohort of patients experiencing an MI in France between 2007 and 2011 was extracted from the échantillon généraliste de bénéficiaires, a 1/97th sample of all beneficiaries of public health insurance in France. RESULTS: A total of 1920 patients experiencing an MI were identified. Two-thirds were men and the mean age was 67 years; 20.6% had diabetes, 37.6% hypercholesterolaemia and 82.4% hypertension. From a societal perspective, the annual costs of medical consumption related to hospitalisations increased from 4548 before the MI to 6470 in the following year. Costs of community care rose from 2932 to 6208. This increase concerned all components of community healthcare: costs associated with medical transportation increased fourfold, those associated with consultations and laboratory tests tripled, medication costs doubled and costs of paramedical services also increased, but to a lesser extent. It should be noted that the cost of hospitalisation for the index MI ( 5876) is not included in the above costs. CONCLUSION: From a society perspective, the cost of healthcare resource consumption increased threefold in the year following an MI.
Subject(s)
Cost of Illness , Health Care Costs , Hospitalization/economics , Myocardial Infarction/economics , Quality of Life , Referral and Consultation/economics , Aged , Female , France , Humans , Male , Retrospective Studies , Risk Factors , Severity of Illness IndexABSTRACT
BACKGROUND: The impact of Clostridium difficile infection (CDI) on healthcare costs is significant due to the extra costs of associated inpatient care. However, the specific contribution of recurrences has rarely been studied. AIM: The aim of this study was to estimate the hospital costs of CDI and the fraction attributable to recurrences in French acute-care hospitals. METHODS: A retrospective study was performed for 2011 on a sample of 12 large acute-care hospitals. CDI costs were estimated from both hospital and public insurance perspectives. For each stay, CDI additional costs were estimated by comparison to controls without CDI extracted from the national DRG (diagnosis-related group) database and matched on DRG, age and sex. When CDI was the primary diagnosis, the full cost of stay was used. FINDINGS: A total of 1067 bacteriological cases of CDI were identified corresponding to 979 stays involving 906 different patients. Recurrence(s) were identified in 118 (12%) of these stays with 51.7% of them having occurred within the same stay as the index episode. Their mean length of stay was 63.8 days compared to 25.1 days for stays with an index case only. The mean extra cost per stay with CDI was estimated at 9,575 (median: 7,514). The extra cost of CDI in public acute-care hospitals was extrapolated to 163.1 million at the national level, of which 12.5% was attributable to recurrences. CONCLUSION: The economic burden of CDI is substantial and directly impacts healthcare systems in France.
